Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 4/20 | 0.39 |
| ▸ | CTSS | P25774 | 2/20 | 0.37 |
| ▸ | CTSK | P43235 | 2/20 | 0.37 |
| ▸ | CTSL | P07711 | 1/20 | 0.37 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
| ▸ | MMP13 | P45452 | 2/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | MMP14 | P50281 | 1/20 | 0.36 |
| ▸ | MME | P08473 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | REN | P00797 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21447959 | 0.91 | POLB (0.37) | CTSSCTSKCTSLCTSBMMP13 | |
| SCHEMBL18248108 | 0.91 | ALDH1A1 (0.41) | CTSSCTSKMMEREN | |
| SCHEMBL18256484 | 0.91 | ALDH1A1 (0.41) | CTSSCTSKMMEREN | |
| SCHEMBL22651717 | 0.88 | CTSK (0.41) | CTSSCTSKCTSLCTSBMMP13 | |
| SCHEMBL18256528 | 0.88 | SYK (0.40) | CTSSCTSKCTSLCTSBMMP13 | |
| SCHEMBL18248075 | 0.88 | SYK (0.40) | CTSSCTSKCTSLCTSBMMP13 | |
| SCHEMBL22502801 | 0.85 | CTSK (0.38) | CTSSCTSKCTSLCTSBMMP13 | |
| SCHEMBL23269885 | 0.84 | MMP13 (0.39) | CTSSCTSKCTSLCTSBMMP13 | |
| SCHEMBL18248083 | 0.84 | CTSK (0.46) | CTSSCTSKCTSLCTSBMMP13 | |
| SCHEMBL21447763 | 0.84 | CTSK (0.46) | CTSSCTSKCTSLCTSBMMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11382949-B2 | Anthelmintic depsipeptide compounds | Boehringer Ingelheim Animal Health USA Inc. (US) | 2022-07-12 | — | — | US | disclosed |
| US-20190307838-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | Boehringer Ingelheim Animal Health USA Inc. (US) | 2019-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11382949-B2 | Anthelmintic depsipeptide compounds | ENPP2, ROCK2, RRP12 | MMP12 1328/4885CTSS 548/4885CTSK 1247/4885 |
| US-20190307838-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | ENPP2, ROCK2, RRP12 | MMP12 1328/4885CTSS 548/4885CTSK 1247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.